|
 Ajovy was approved by the U.S. Food and Drug Administration (FDA) in
September last year and the company had said it was seeing "a very
strong launch" of the treatment.
"A final decision is expected in the first half of 2019," Teva said.
Ajovy had suffered a setback in October when Express Scripts Holding
Co, one of the largest U.S. prescription benefits managers, said it
will cover new migraine drugs from Eli Lilly and Amgen Inc but not
from Teva.
[to top of second column] |
While final approvals are up to the European Commission, it
generally follows the CHMP's recommendation and endorses them within
a couple of months.
(Reporting by Sangameswaran S in Bengaluru; Editing by Anil D'Silva)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
